The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., July 13, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. The agreement will result in the dismissal of all pending cases or appeals […]
ABBOTT PARK, Ill., July 6, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including […]
— Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision — Imaging techniques such as OCT have been shown to improve outcomes during stenting procedures¹, but remain underutilized in global clinical settings due to lack […]
– New data reinforce Abbott’s leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies – Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott’s innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings ABBOTT PARK, Ill., June […]
– First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent – Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19) ABBOTT PARK, Ill., April 16, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2020. First-quarter worldwide sales of $7.7 billion increased 2.5 percent on […]
– CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition – New system offers a proven safe and effective minimally invasive non-surgical solution – The TriClip System leverages Abbott’s proven clip-based technology used in its MitraClip™ transcatheter mitral valve therapy […]
– New FlexNav™ delivery system improves control and delivery of the Portico™ TAVI valve even in complex clinical cases – The minimally invasive Portico procedure allows doctors to treat severe aortic valve stenosis without invasive surgery – Approval of the new delivery system follows first implants of the company’s next-generation […]
– New Gallant™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patient’s unique clinical needs – Gallant ICD and CRT-D devices feature a more comfortable design, preferred by patients without compromising on battery longevity or high-voltage […]
ABBOTT PARK, Ill., Feb. 4, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development Fully Implantable Left Ventricular Assist System (FILVAS). The FDA launched the Breakthrough Devices Program in 2018 to help expedite the development and review […]
– The CATALYST trial will examine Abbott’s Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation ABBOTT PARK, Ill., Feb. 3, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration […]
